India reopens PLI scheme for medical devices, extends it to 2035-36

The department has also scaled down the baseline capital expenditure required from manufacturers. Together, the two changes lower the entry barrier for companies that want to build or expand domestic production of medical devices.

Why it matters

Lighter investment and sales conditions are likely to matter most for smaller and newer manufacturers, which often find it harder to commit large sums upfront or to prove scale quickly. A longer runway to 2035-36 also gives companies more time to plan investments and to recoup them while still being eligible for incentives.

The reopening of the application window gives firms that did not take part earlier, or that were deterred by the original conditions, another chance to apply under the revised terms.

What comes next

Companies interested in the scheme will need to review the revised guidelines issued by the Department of Pharmaceuticals and submit fresh applications. Details such as the application deadline and the exact revised capital expenditure levels were not included in the information available at the time of writing.